Author: Ravi Shankar

Individual co-investor matches RYET’s RMB 1 million commitment; approximately 400 scripts and 30 AI films planned for international distribution through Formind

KUALA LUMPUR, Malaysia, Nov. 11, 2026 (GLOBE NEWSWIRE) — Ruanyun Edai Technology Inc. (NASDAQ: RYET) (“RYET” or the “Company”) announced that its consolidated variable interest entity, Jiangxi Ruanyun Technology Co., Ltd. (“Jiangxi Ruanyun”), has entered into a cooperation agreement to develop, produce and commercially release AI-assisted scripts and AI films using the Company’s YeeZo platform. Jiangxi Ruanyun and its co-investor have each committed RMB 1 million, for a total first-phase budget of RMB 2 million. Neither party receives a guaranteed return or priority repayment of its capital; both are paid only from the program’s profits.

The program combines specialized large language models with human writers and editors. Over an initial 12-month plan, RYET intends to develop approximately 400 new and adapted film and television scripts, from topic selection through writing and review, for sale and licensing. It also intends to acquire and adapt screenplays for approximately 30 AI films to be produced with AI tools and released through YouTube and other platforms. Specific titles will be chosen during the program on the basis of market research, production testing and commercial value.

The first-phase budget allocates RMB 1.2 million to AI film production, RMB 450,000 to acquiring and licensing base screenplays, RMB 200,000 to model usage, tokens and computing power, and RMB 150,000 to building a dedicated AI script-production capability on YeeZo.

“YeeZo was built to turn AI tools into disciplined production: stories, roles, review, rights and delivery. This program applies that approach where it counts, in scripts and films that have to find buyers and audiences. A partner putting capital alongside ours, with no guaranteed return, gives the program a clear commercial test from the start.”

Maggie Fu, Chief Executive Officer, Ruanyun Edai Technology Inc.

Direct Entry into Content Creation & Production

The agreement treats script production, film production and their commercialization as a single program. Program revenue may include script sales, licensing and adaptation fees, film distribution and licensing income, and advertising revenue shares from YouTube and other video platforms. Cumulative operating profit, after actual program costs and taxes, is shared 60% to Jiangxi Ruanyun and 40% to the co-investor and settled quarterly. Profit sharing continues after the first phase while completed works are sold, licensed and distributed.

RYET, through Jiangxi Ruanyun, manages the program, including title selection, production, distribution and pricing, and is responsible for rights clearance and compliance with AI-content and platform rules. The co-investor receives monthly reports and has inspection rights. Rights in program scripts are held 60% by Jiangxi Ruanyun and 40% by the co-investor, and rights in program films are held equally. The YeeZo platform and its software, models, workflows and other technology remain solely with Jiangxi Ruanyun.

The Company believes the co-investor’s decision to commit capital on these terms, without a guaranteed return, reflects confidence in YeeZo’s production model and its commercial potential.

International Distribution Through Formind

Program scripts and films are expected to be distributed outside China by Formind Global Holdings Sdn. Bhd. (“Formind Global”), the Company’s Malaysian subsidiary. Distribution is expected to take place through international video platforms, licensees and other partners. Income from program works, including international distribution, remains program income and is shared under the agreement.

Formind Global was established in Malaysia in 2026 as part of the operating platform for the Company’s planned global headquarters. Under the Formind Group identity, the Company is building an international business that connects AI applications, education and industry, working with partners that understand local language, regulation and customer needs. The program extends that strategy from education into commercial content, with Formind Global intended to connect production in China with audiences and buyers in other markets.

Demand for scripted short-form video has grown quickly. An official of China’s National Radio and Television Administration said in February 2026 that the country’s micro-drama market exceeded RMB 100 billion in 2025, roughly double the previous year, with about 33,000 new micro-dramas and nearly 700 million domestic users. Internationally, Sensor Tower reported in January 2026 that downloads of short drama apps grew 278% in 2025. The Company believes this demand creates an opportunity for scripts and films produced efficiently with AI and refined through human review.

Moving Beyond Training into Agentic Content Development

The Company introduced YeeZo in May 2026 as a workflow and orchestration platform for AIGC storyboarding, content planning and multi-model production. In August 2026, it launched the YeeZo University AI Content Training Program to bring production discipline into university teaching. The new program applies YeeZo to commercial production, where workflows, human review and rights management determine whether AI-assisted work can be sold and distributed.

The 12-month plan moves from platform preparation and screenplay acquisition, through sample validation and batch script production, to AI film production, distribution and commercial validation from the fourth month. Production numbers and timing are planning targets that may change with production efficiency, quality and market response, and are not financial guidance. The agreement does not commit any buyer, licensee or platform to acquire or distribute program works.

About Ruanyun Edai Technology Inc.

Ruanyun Edai Technology Inc. is an AI-driven education technology company focused on intelligent content recognition, automated assessment and next-generation learning systems. The Company has historically developed and provided AI-enabled teaching, learning and assessment solutions, including smart homework, smart examination and digital education services, and since September 2025 has provided campus operations and student-life services through its Smart Campus Services business. The Company is presenting its group businesses under the Formind Group identity as part of its broader strategy to expand AI education, language learning, institutional education support and global technology initiatives. Additional information about Formind Group is available at www.formind.group. Information on that website is not part of this press release.

Forward-Looking Statements

This press release contains forward‑looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 and applicable securities laws. All statements other than statements of historical fact are forward‑looking statements. Forward‑looking statements may be identified by words such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “goal,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar expressions.

These statements include, among others, statements regarding the implementation, scope, timing, budget and anticipated benefits of the AI script and film program; script and film production targets; the funding of the program; the selection, acquisition, adaptation, production, distribution and commercialization of scripts and films; international distribution through Formind Global; potential revenue from script sales, licensing, platform advertising and distribution; the sharing of profits and intellectual-property rights; market demand for short-form video; and the development and commercialization of YeeZo and the Company’s Formind strategy.

Forward-looking statements are based on current expectations, estimates and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Relevant risks include the parties’ performance of their funding and other obligations; the Company’s ability to produce scripts and films of commercial quality within budget and on schedule; market acceptance and audience demand, which may not follow third-party market estimates; Formind Global’s ability to establish international distribution; reliance on YouTube and other third-party platforms and their rules on AI-generated content, copyright and monetization; uncertainty over copyright protection for AI-generated content; third-party intellectual-property, likeness and voice rights; reliance on third-party AI models; PRC and other laws governing audiovisual content, AI-generated content, cross-border distribution and data; risks relating to the Company’s contractual arrangements with its variable interest entity in China; and the tax and accounting treatment of the arrangement. The agreement does not assure any sale, license, distribution arrangement, audience or particular financial result.

Forward-looking statements speak only as of the date of this release. Additional risks are described in the Company’s reports filed with or furnished to the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 20-F. The Company undertakes no obligation to update any forward-looking statement except as required by law.

Investor Relations and Corporate Communications

FSR Capital, a FSR Group Company
Email: ir@fsr.group

Company completes additive manufacturing facility buildout, advances proprietary silicon nitride–PEEK technology, expands leadership and targets initial product availability in 2027 

SALT LAKE CITY, Utah, Nov. 11, 2026 (GLOBE NEWSWIRE) — SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), an advanced ceramics and biomaterials technology company focused on silicon nitride-based solutions, today provided a strategic business update on the continued product development and planned commercialization of its proprietary silicon nitride–polyetheretherketone (SiN/PEEK) composite technology through its SiNERGY^™ additive manufacturing platform.

SINTX has completed the buildout of its advanced 3D printing facility, received its EXT-220 MED medical-grade additive manufacturing systems, expanded its technical leadership, and advanced discussions with potential engineering and international commercialization partners. These developments support the Company’s strategy to develop an integrated platform combining proprietary biomaterials, AI-assisted surgical planning, patient-specific implant design, and advanced manufacturing.

The Company anticipates receiving its proprietary SiN/PEEK compounded filament from Evonik before year-end 2026 and is pursuing FDA 510(k) clearance for a defined design envelope of patient-specific extremity implants. The Company is evaluating limited opportunities for qualifying custom devices in the first quarter of 2027. Broader commercial distribution of patient-specific implants will require applicable regulatory clearances and manufacturing validation. The Company anticipates expansion into craniomaxillofacial (CMF) and spinal applications later in 2027, subject to regulatory review and other factors.

“We believe our SiN/PEEK technology represents a potentially significant commercial growth opportunity for SINTX,” said Eric K. Olson, Chairman and Chief Executive Officer of SINTX Technologies. “We are bringing together years of proprietary biomaterials research, differentiated intellectual property, advanced additive manufacturing, and personalized surgical technologies to establish an integrated commercial platform. Our objective is to deliver patient-specific solutions that combine the design flexibility of 3D printing with the unique biological and mechanical properties of silicon nitride.”

Advancing a Differentiated Biomaterials Platform
At the core of SINTX’s strategy is its proprietary SiN/PEEK composite, which combines the established structural and imaging characteristics of medical-grade PEEK with silicon nitride, a bioactive ceramic that has exhibited antibacterial and osteogenic properties in laboratory studies.

Silicon nitride has been extensively studied for its surface chemistry, resistance to bacterial adhesion and biofilm formation, hydrophilicity, and ability to support osteoblast activity and bone-related mineralization. Incorporating silicon nitride into PEEK is intended to potentially provide beneficial biological characteristics while retaining the design flexibility, radiolucency, and structural characteristics that have made PEEK an established material for orthopedic implants.

SINTX’s published in vitro research with SiN/PEEK composites reported reduced bacterial adhesion, supported enhanced osteogenic cellular activity, and maintained mechanical properties relevant to orthopedic implant applications under the conditions tested. In one published investigation involving 3D-printed SiN/PEEK spinal cage designs, researchers reported a 93.9% reduction in bacterial adhesion compared with conventional PEEK under the laboratory conditions tested, together with enhanced cell proliferation.

These findings build upon years of SINTX research and support the Company’s intellectual property portfolio, including patents covering SiN/PEEK compositions and related methods. The Company believes this combination of proprietary material science and additive manufacturing capabilities may provide meaningful differentiation in the growing market for personalized orthopedic devices.While these laboratory findings are encouraging, their clinical significance for individual implant applications will require appropriate product-specific evaluation and validation.

Establishing Advanced Manufacturing and Technical Leadership
To support commercialization, the Company has also appointed James A. Smith, Ph.D., as Director of 3D Additive-Manufacturing, strengthening its expertise in high-performance personalized orthopedic implant development.

Dr. Smith brings specialized experience in PEEK additive manufacturing, polymer composites, mechanical characterization, and patient-specific medical device development. His academic and research experience includes work associated with Drexel University, as well as published investigations into additively manufactured PEEK cranial implants, orthopedic structural composites, and silicon nitride-related biomaterials. He earned his Ph.D. in additive manufacturing and mechanical engineering from Loughborough University.

Dr. Smith will lead the Company’s additive manufacturing initiatives, including process development, material optimization, manufacturing validation, and the advancement of its custom and patient-specific implant portfolio.

SINTX is also in discussions with a specialized engineering services firm to support AI-assisted medical image segmentation, anatomical modeling, and patient-specific implant design. If developed and successfully integrated, these capabilities are intended to create a streamlined digital workflow connecting patient imaging and surgical planning with individualized implant design and manufacturing.

Outlook
Over the coming quarters, SINTX expects to focus on completing manufacturing process development and validation, receiving its proprietary SiN/PEEK filament, integrating digital engineering capabilities, and advancing its initial custom implant and surgical guide portfolio toward commercial distribution.

The Company’s longer-term strategy includes obtaining FDA 510(k) clearance for defined families of patient-specific extremity implants, expanding into CMF and spinal applications, and developing additional manufacturing, distribution, and technology partnerships.

Management considers the SiNERGY^™ SiN/PEEK platform a central component of SINTX’s long-term strategy to build a diversified medical technology business leveraging its proprietary biomaterials and advanced manufacturing capabilities.

About SINTX Technologies, Inc.

Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics and biomaterials company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. SINTX’s technologies are supported by peer-reviewed research, a patent portfolio, U.S.-based manufacturing capabilities, and strategic industry relationships. The Company’s business includes proprietary biomaterials and medical device technologies, as well as contract manufacturing and other advanced ceramics opportunities. SINTX’s product portfolio includes the FDA-cleared SiNAPTIC^® Foot & Ankle Osteotomy Wedge System for reconstructive surgery. For more information, visit www.sintx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements can be identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “may,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and on predictions as to future facts and conditions. Forward-looking statements in this release include, without limitation, statements regarding the development, regulatory clearance, and commercialization of the Company’s SiN/PEEK composite technology and SiNERGY^™ additive manufacturing platform; the anticipated receipt of the Company’s SiN/PEEK filament from Evonik before year-end 2026; the targeted initiation of commercial distribution of custom extremity implants and surgical cutting guides in the first quarter of 2027; the Company’s pursuit of FDA 510(k) clearance for a defined design envelope of patient-specific extremity implants and its planned expansion into craniomaxillofacial and spinal applications later in 2027; the Company’s plans to supply certain products under the FDA custom device exemption; the status and potential of discussions regarding AI-assisted implant-design, engineering, and international manufacturing and distribution partnerships; the expected benefits and differentiation of the Company’s integrated platform; and the potential for recurring product revenue and strategic collaborations. These statements are based on management’s current expectations, estimates, and assumptions and are subject to inherent risks, uncertainties, and changes in circumstances that could cause actual results to differ materially from those contemplated or implied by such statements. These risks and uncertainties include, among others: the Company’s ability to obtain FDA 510(k) clearance or other required regulatory clearances or approvals on the anticipated timeline, in the anticipated scope, or at all, and the fact that the Company may not market any product requiring 510(k) clearance until FDA issues a substantial-equivalence determination; the limits and conditions of the FDA custom device exemption; the Company’s dependence on Evonik and other third parties for the timely supply of SiN/PEEK filament, components, and equipment; the Company’s ability to complete manufacturing process development and validation and to manufacture products at commercial scale; the risk that laboratory, in vitro, or preclinical findings do not translate into clinical or commercial performance; the risk that preliminary partnership discussions do not result in definitive agreements; the Company’s ability to secure and execute licensing and commercialization partnerships; the Company’s ability to protect and enforce its intellectual property; the Company’s ability to obtain sufficient funding and to continue as a going concern; competition, reimbursement availability, surgeon adoption, commercial pricing, manufacturing costs, distribution capabilities,and the degree of market acceptance of personalized orthopedic devices; and general economic and market conditions. Additional risks and uncertainties are described in the Company’s filings with the U.S. Securities and Exchange Commission, including under “Risk Factors” in its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statement as a result of new information, future events, or otherwise, except as required by applicable law, and readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release.

Company Contact:
Andrew Benson
SINTX Technologies, Inc.
801.839.3500
IR@sintx.com

Signed Agreements with Artesia Group and Phoenix Energy Solutions Advance Previously Announced Commercial Opportunity

Dallas, TX, Nov. 11, 2026 (GLOBE NEWSWIRE) — Vivakor, Inc. (Nasdaq: VIVK) (“Vivakor” or the “Company”), an integrated provider of energy transportation, storage, reuse and remediation services, today reported that Direct Midstream, LLC (“Direct Midstream”), the subject of Vivakor’s previously announced proposed $40 million acquisition, has finalized definitive operating agreements with Artesia Group, LLC (“Artesia”) and Phoenix Energy Solutions, LLC (“PES”) covering a 52-well portfolio in New Mexico.

As announced by Direct Midstream on November 9, 2026, the agreements formalize its previously announced conditional arrangement with PES and establishes Direct Midstream as the contract operator for Artesia, the current asset owner, and PES following its anticipated acquisition of the assets.

The portfolio consists of 44 oil production wells and eight saltwater disposal wells, subject to verification. The agreements are expected to expand Direct Midstream’s existing New Mexico operations and add oil production operating services to its produced water management and disposal capabilities. Direct Midstream estimates the opportunity could generate more than $2 million in annual operating and management service revenue at targeted operating levels, subject to final fee arrangements.

“We are encouraged by Direct Midstream’s continued commercial progress as we work toward our proposed acquisition,” said James Ballengee, Chairman, President and Chief Executive Officer of Vivakor. “These agreements represent a meaningful step in expanding Direct’s operating capabilities and creating opportunities for recurring service revenue. We believe this progress further supports the strategic rationale for our proposed acquisition and the potential integration of Direct Midstream into Vivakor’s energy infrastructure platform.”

Direct Midstream is submitting change-of-operator filings to the New Mexico Oil Conservation Division. Direct Midstream intends to commence operations upon receipt of applicable regulatory approvals, including Bureau of Land Management approval for any federal wells. Projected production volumes, water volumes and service revenue are estimates and are not guaranteed.

Vivakor’s proposed acquisition of Direct Midstream remains subject to execution of a definitive purchase agreement, funding of the contemplated capital investment and satisfaction of other applicable conditions. There can be no assurance that the acquisition will be completed.

About Direct Midstream

Direct Midstream is a provider of midstream energy and fluid management services serving oil and gas operators throughout the Permian Basin. The company’s services include saltwater disposal, produced water management, oil recovery and reclamation, slop oil processing and related oilfield waste services. Direct Midstream utilizes Class II UIC wells, automation and advanced monitoring systems to support safe, efficient and environmentally responsible operations.

For more information, please visit the website: https://directmidstream.com

About Vivakor, Inc.

Vivakor, Inc. is an integrated provider of sustainable energy transportation, storage, reuse, and remediation services. Its corporate mission is to develop, acquire, accumulate, and operate assets, properties, and technologies in the energy sector. Vivakor’s integrated facilities assets provide crude oil, storage, transportation, reuse, and remediation services under long-term contracts. Once operational, Vivakor’s interest in oilfield waste remediation facilities will facilitate the recovery, reuse, and disposal of petroleum byproducts and oilfield waste products.

For more information, please visit our website: http://vivakor.co

Cautionary Statement Regarding Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements. Forward-looking statements may be identified but not limited by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” and variations or similar expressions. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including, but not limited to, the expected transaction and ownership structure, the valuation of the transaction, the likelihood and ability of the parties to successfully and timely consummate planned acquisitions, the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect Vivakor or the expected benefits of the such transaction, our ability to maintain the listing of our securities on The Nasdaq Capital Market, the parties failure to realize the anticipated benefits of pending transactions, disruption and volatility in the global currency, capital, and credit markets, changes in federal, local and foreign governmental regulation, changes in tax laws and liabilities, tariffs, legal, regulatory, political and economic risks, our ability to successfully develop products, rapid change in our markets, changes in demand for our future products, and general economic conditions.

These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor’s filings with the U.S. Securities and Exchange Commission, which factors may be incorporated herein by reference. Actual results, performance or achievements may differ materially, and potentially adversely, from any projections and forward-looking statements and the assumptions on which those forward-looking statements are based. There can be no assurance that the data contained herein is reflective of future performance to any degree. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance as projected financial information and other information are based on estimates and assumptions that are inherently subject to various significant risks, uncertainties and other factors, many of which are beyond our control. All information set forth herein speaks only as of the date hereof in the case of information about Vivakor or the date of such information in the case of information from persons other than Vivakor, and we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication. Forecasts and estimates regarding the industries and markets are based on sources we believe to be reliable; however, there can be no assurance these forecasts and estimates will prove accurate in whole or in part.

Investor Contact:
P:469-480-7175
info@vivakor.com

Approximately 95% of Outstanding Convertible Note Principal Committed to Conversion, Subject to Completion of a Strategic Merger

Sequence LifeScience^™ Provides $732,000, Representing 61% of Approximately $1.2 Million Funded to Date, in
Support of a Strategic Merger

LANGHORNE, Pa., Nov. 11, 2026 (GLOBE NEWSWIRE) — NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a company with a patient-centric medical technology sales and marketing team working closely with clinicians to provide solutions that drive better outcomes, streamline care and elevate the patient experience, today announced significant progress in its strategic recapitalization, with noteholders representing approximately 95% of the Company’s outstanding convertible note principal having executed agreements to convert their notes into common stock, subject to completion of a strategic merger and other conditions.

Holders representing approximately $14.125 million of the Company’s $14.885 million of outstanding convertible note principal have executed conversion agreements. Participating noteholders have also agreed to receive accrued interest through September 30, 2026 in common stock rather than cash upon conversion, further preserving liquidity for the Company. Interest accruing from October 1, 2026 is suspended and will not be payable if the conversion occurs. Upon completion of a strategic merger and satisfaction of the applicable conversion conditions, the conversion is expected to substantially reduce the Company’s outstanding debt, preserve liquidity and strengthen its balance sheet.

The Company has received total commitments of approximately $1.276 million, with $1.2 million of that amount funded to date, with total commitments of approximately $1.276 million, from existing NEXGEL noteholders participating in the recapitalization and NEXGEL’s strategic partner, Sequence LifeScience™. Sequence, which previously led the Company’s convertible note financing, funded approximately $732,000, representing 61% of the $1.2 million funded to date. Sequence is wholly owned by Brian Kieser, NEXGEL’s Interim Chief Executive Officer and a director. The financing consists of purchases of NEXGEL common stock at a fixed purchase price of $5.50 per share, together with 100% warrant coverage at an exercise price of $10.00 per share.

The initial financing is intended to provide the Company with liquidity to support transaction costs and the immediate operational and strategic work necessary to pursue a strategic merger. The additional investment also represents continued financial participation from stakeholders already supporting the Company’s strategic direction. Collectively, the recapitalization, financing commitments and operational initiatives are intended to improve the Company’s capital structure, liquidity profile and operating efficiency.

“Achieving approximately 95% participation from our noteholders represents a significant milestone in NEXGEL’s recapitalization and reflects strong support for the path we are pursuing,” said Kevin Harris, Chair of the Special Committee for Strategic Review and Value Creation of the NEXGEL Board of Directors. “The conversion of approximately $14.1 million of existing debt would substantially reduce the debt burden on NEXGEL’s balance sheet. Combined with the new capital received and additional commitments, we believe we are establishing a significantly stronger financial foundation from which to pursue our contemplated strategic merger.”

Brian Kieser, Interim Chief Executive Officer of NEXGEL, added, “Our progress extends beyond the balance sheet. Since beginning the strategic review and leadership transition, we have implemented approximately $2.25 million of annualized cost savings and are pursuing up to an additional $1.75 million of savings and reductions in losses from underperforming operations. Together, these actions are creating a leaner operating structure and positioning NEXGEL to execute on its next phase of growth.”

The Company anticipates that additional growth capital may be raised in connection with the closing of the contemplated strategic merger. Such additional capital would be intended to provide liquidity to support the combined company’s operations, integration and growth initiatives following the merger.

The Company is currently considering a strategic merger with Fountainhead LifeSciences and its affiliates, including Sequence and NVISION Biomedical Technologies, Inc., which would be a related party transaction. If the merger is not completed by March 31, 2027 (subject to extension), the noteholder conversions referenced above will not occur and the notes will remain outstanding, and shares purchased in the new capital financing will be exchanged for convertible notes.

The Company’s ability to close the contemplated strategic merger, or any strategic merger at all, remains subject to the negotiation and execution of definitive agreements, applicable corporate and regulatory approvals and other customary closing conditions. There can be no assurance that any strategic merger will be consummated on the currently contemplated terms or at all.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.

These securities are being sold in a private placement and have not been registered under the Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from such registration requirements.

Additional information regarding these transactions, including the terms of the related agreements, is included in the Company’s Current Report on Form 8-K will be filed with the Securities and Exchange Commission October 12, 2026.

About NEXGEL, Inc.

NEXGEL, through its Bionx Surgical division, is a patient centric medical technology sales and marketing team working closely with clinicians to provide solutions that drive better outcomes, streamline care, and elevate the patient experience. Bionx has a strong offering of products including Biovance (human amniotic membrane allograft), Biovance 3L (tri-layer human amniotic membrane allograft), Interfyl (human connective tissue matrix), SilverSeal (antimicrobial hydrogel wound dressing), and an expansive ophthalmic portfolio of placental derived ocular allografts (LUCENT, single layer, RADIANT, dual layer, and VIVID, triple layer). Additionally, NEXGEL is a provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. In addition to the above, NEXGEL brands include Hexagels^®, Turfguard^®, Kenkoderm^® and Silly George^®. NEXGEL also has strategic contract manufacturing relationships with leading consumer healthcare companies.

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, statements regarding the anticipated conversion of the Company’s outstanding convertible notes, the completed and anticipated additional funding under the new capital financing, the anticipated effect of the recapitalization on the Company’s balance sheet and liquidity, the Company’s pursuit of the contemplated strategic merger, the potential consummation and timing of such merger, and the Company’s ability to raise additional growth capital in connection with any such merger. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the Securities and Exchange Commission and which may be viewed at SEC.gov.

Investor Contact:

Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@kcsa.com

First U.S. commercial aquatics installation marks a key milestone in LiqTech’s international expansion

BALLERUP, Denmark, Nov. 11, 2026 (GLOBE NEWSWIRE) — LiqTech International, Inc. (Nasdaq: LIQT) (“LiqTech”), a clean technology company specializing in advanced filtration technologies, today announced that installation of its three QlariFlow™ ceramic membrane filtration systems is underway at Worland Aquatic Center in Worland, Wyoming.

The project follows the order announced on March 23, 2026, and represents LiqTech’s first commercial aquatics installation in the United States. Delivered in collaboration with Treatment Specialties – Powered by North American Filtration, this milestone marks a significant step in LiqTech’s strategy to expand its presence in the U.S. commercial swimming pool market.

QlariFlow combines LiqTech’s proprietary silicon carbide ceramic membrane technology with a compact, modular system design. The platform is designed to deliver consistently high water quality while reducing water, energy and chemical consumption compared with conventional media filtration systems. Its compact footprint also makes it particularly suitable for facilities with limited equipment space.

“The installation of our first commercial aquatics system in the United States represents an important milestone in our international growth strategy,” said Fei Chen, CEO of LiqTech. “The U.S. commercial swimming pool market offers significant opportunities for advanced filtration technologies that improve water quality and resource efficiency. Together with our local partner, Treatment Specialties, we are establishing an important reference installation that we believe will support further market development and commercial growth.”

Following commissioning, the Worland Aquatic Center installation is expected to serve as a key U.S. reference for the QlariFlow platform, strengthening LiqTech’s position in the commercial aquatics market and supporting the development of additional opportunities through its regional distribution network.

About LiqTech International Inc.

LiqTech International, Inc., a Nevada corporation, is a high-tech filtration technology company that provides state-of-the-art ceramic silicon carbide filtration technologies for gas and liquid purification. LiqTech’s silicon carbide membranes are designed to be used in the most challenging purification applications, and its silicon carbide filters are used to control diesel exhaust soot emissions. Using nanotechnology, LiqTech develops products using its proprietary silicon carbide technology, resulting in a wide range of component membranes, membrane systems, and filters for both microfiltration and ultrafiltration applications. By incorporating LiqTech’s SiC liquid membrane technology with the Company´s extensive systems design experience and capabilities, LiqTech offers unique, modular designed filtration solutions for the most difficult water purification applications.

For more information, please visit www.liqtech.com 

Follow LiqTech on LinkedIn: http://www.linkedin.com/company/liqtech-international 

Follow LiqTech on X: https://x.com/LiqTech

Forward–Looking Statement

This press release contains “forward-looking statements.”  Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements.  Readers are urged to carefully review and consider the various disclosures made by us in the reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation, and cash flows.  If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.  Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.

We assume no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

LiqTech Company Contact                                         
Susan Keegan Elleskov
Head of Marketing
LiqTech International, Inc.
Phone: +45 31315941
www.liqtech.com

LiqTech Investor Contact                                         
Robert Blum
Lytham Partners, LLC                                 
Phone: 602-889-9700
liqt@lythampartners.com

SRR supports continued systems engineering and integration activities

SAN DIEGO, Nov. 11, 2026 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in the defense, national security and global markets, today announced it has successfully completed the System Requirements Review (SRR) supporting the U.S. Space Force’s (USSF) Space Systems Command (SSC) Ground Management and Integration (GMI) effort for the Resilient Missile Warning and Tracking (MWT) program.

The SRR is a technical milestone supporting continued requirements development, systems engineering, and integration planning for the GMI effort. Kratos completed the SRR within the planned review period.

Kratos used advanced digital engineering and model-based systems engineering (MBSE) tools to support the review process, including requirements development and system-integration planning. The work supports an open, interoperable approach intended to enable integration across multiple space and ground segments.

The GMI effort supports development of resilient, integrated ground architecture for the Resilient MWT program. Kratos is integrating their unique ground system with the SSC Future Operationally Resilient Ground Evolution (FORGE) platform to support evolving constellation and mission requirements.

The SRR supported continued systems engineering and integration activities for the GMI effort, ensuring that stronger missile warning and tracking capabilities will be delivered to the Joint warfighter.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com and follow Kratos on LinkedIn and X.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 28, 2025, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Cantrell
claire.cantrell@kratosdefense.com

Kratos Investor Information:
877-934-4687
investor@kratosdefense.com

SAN JOSE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) — QuantumScape Corporation (NASDAQ: QS), a global leader in solid-state lithium-metal battery technology, today announced Osprey: its next-generation open platform for all-solid-state batteries. Osprey cells have delivered the world’s first public data demonstrating a sulfide-based cathode cycling 1,000 times under just one atmosphere of pressure – an unmatched capability that is necessary for automotive solid-state batteries.

Osprey pairs the QS proprietary ceramic separator and anode-free lithium-metal design with a solid cathode, creating an all-solid-state cell. Osprey builds on the company’s QSE platform, and opens new licensing and co-development options for current QS customers and expanding its offering to developers of sulfide-based all-solid-state batteries.

QS technology has demonstrated an enhanced safety profile compared to conventional lithium-ion cells, along with low operating pressure and excellent energy retention. Osprey’s all-solid cathode, paired with the proprietary QS ceramic separator, enables additional performance benefits, including faster charging, operation across a wider range of temperatures, and projected energy densities up to ~1,100 Wh/L.

In early testing, Osprey cells have demonstrated:

• Cycle life: 1,000 full charge cycles with ~80% capacity retention under gold-standard testing conditions
• Fast charging: 10% to 80% in five-minutes
• Low pressure: Requires only one atmosphere of pressure
• Cold-weather performance: Operational to less than -20 °C (-4 °F)

More information, including test results and conditions, can be found in a new white paper.

The battery industry has long pursued all-solid-state batteries using sulfide-based electrolytes, but this has yet to result in a commercially viable technology. Sulfides can react with lithium metal, which shortens battery life, and they typically need to be held under high pressure to operate, which is impractical for vehicles and many other applications.

Osprey is conceived as an open platform capable of working with a range of cathode chemistries. QS has tested Osprey with all-solid cathodes developed both in-house and by its automotive customers, laying the groundwork for multiple technology pathways for solid-state battery development.

“Osprey is the result of years of frontier R&D efforts, and we’re excited to share it publicly for the first time,” said Dr. Siva Sivaram, president and CEO of QS. “The industry has invested heavily in sulfide-based batteries but keeps hitting the same fundamental limits. As the data shows, Osprey can address these limitations. We believe Osprey can unlock the full potential of all-solid-state batteries, and our goal is to make it the leading platform for solid-state battery development.”

QS is already working with partners across the automotive industry on development using the Osprey platform. Cells based on the company’s QSE platform are shipping to customers today, and Osprey represents its long-term technology solution for all-solid-state battery development.

About QuantumScape Corporation
QuantumScape is on a mission to revolutionize energy storage to enable a sustainable future. The company’s next-generation solid-state lithium-metal battery technology is designed to enable greater energy density, faster charging and enhanced safety to support the transition away from legacy energy sources toward a lower carbon future. For more information, visit www.quantumscape.com.

Forward-Looking Statements
Certain information in this press release may be considered “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the company’s expectations for the Osprey platform, including its anticipated performance characteristics such as projected energy density, fast charging, cycle life, operating pressure and temperature range, its cathode cross-compatibility, the potential for licensing and co-development arrangements with current customers and developers of sulfide-based all-solid-state batteries, the company’s development work with automotive partners, the company’s goal of making Osprey the leading platform for solid-state battery development, the role of Osprey as the company’s long-term technology solution, and the commercialization and scaling of its solid-state lithium-metal battery technology, including the QSE platform. These forward-looking statements are based on management’s current expectations, assumptions, hopes, beliefs, intentions and strategies regarding future events and are based on currently available information as to the outcome and timing of future events. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements due to various risks, including the successful development and commercialization of our solid-state battery technology, achieving technical and financial milestones, whether results from early testing of Osprey cells can be replicated in commercial cell formats or at scale, scaling production, the performance of third-party partners and suppliers, including developers of cathode materials, our ability to enter into licensing or co-development arrangements on acceptable terms or at all, achieving the performance, quality, consistency, reliability, safety, cost and throughput required for commercial production and sale, changes in financial conditions, market demand for EVs and other energy storage applications, retaining key personnel, competition, including from other solid-state and sulfide-based battery technologies, regulatory changes, broader economic conditions, and other factors, including those discussed in the section titled “Risk Factors” in our Annual Report and Quarterly Reports and other documents filed with the Securities and Exchange Commission from time to time. Except as otherwise required by applicable law, the company disclaims any duty to update any forward-looking statements.

Contacts:

For Investors ir@quantumscape.com

For Media media@quantumscape.com

TruNorth Aerospace & Defense USA and TruNorth Kaizen to support production acceleration and long-term manufacturing capability through lean expertise

TORONTO, Nov. 11, 2026 (GLOBE NEWSWIRE) — Martinrea International Inc. today announced that TruNorth Aerospace & Defense USA, together with TruNorth Kaizen, both wholly owned U.S. companies of Martinrea International, has established a working relationship with Raytheon, an RTX business, to help accelerate Tomahawk^® cruise missile production.

TruNorth will work alongside Raytheon’s manufacturing operations teams to apply proven lean principles, processes and tools to strengthen manufacturing performance. This work will include sharing manufacturing knowledge and leadership operating principles to support long-term growth.

The collaboration will streamline manufacturing flow, line design and production processes to increase efficiencies and shorten production lead time. This will strengthen daily work practices and workforce development, helping Raytheon continue to scale production to meet the needs of the U.S. Department of War.

“This effort demonstrates the strength of what Martinrea does every day: operate world-class manufacturing plants,” said Pat D’Eramo, chief executive officer of Martinrea International. “Raytheon is accelerating munitions production while continuing to build the capacity and infrastructure required to respond to increasing demand across the defense industry. Our team brings deep lean operating experience to help make that happen. By working together, we can identify opportunities, implement practical solutions and transfer knowledge that help achieve these goals.”

TruNorth began working with Raytheon in the summer of 2026, initially applying its lean manufacturing methodology within Raytheon’ operations. Early results from that work led to a broader engagement focused on embedding lean principles and operating efficiencies more deeply across Raytheon’s manufacturing organization.

“This is an important step into the defense space,” said Rob Wildeboer, executive chairman of Martinrea International. “Our newly formed U.S. subsidiary, TruNorth Aerospace & Defense USA, has great potential. The opportunity goes beyond supporting today’s production requirements. It is about helping build the manufacturing strength needed to respond to the evolving needs of the industry. Over time, we also see opportunities to become a direct manufacturing supplier to leading aerospace and defense companies.”

For Raytheon, the collaboration supports a broader focus on strengthening manufacturing readiness and developing the people, processes and operating systems required to respond to changing production needs.

“Our customers are counting on us to deliver critical capabilities when and where they are needed most. That means increasing production, accelerating delivery and bringing greater urgency to everything we do,” said Bob Butz, senior vice president for operations, supply chain and quality at Raytheon. “This collaboration with TruNorth will help us continue to increase production and enhance team effectiveness so that we can deliver the combat-proven systems our warfighters need.”

ABOUT MARTINTEA INTERNATIONAL INC.

Martinrea International Inc. (TSX: MRE) is a diversified and global automotive supplier engaged in the design, development and manufacturing of highly engineered, value-added Lightweight Structures and Propulsion Systems. Martinrea operates in 53 locations including Canada, the United States, Mexico, Germany, Slovakia, Spain, South Africa and Japan. Martinrea’s vision is making lives better by being the best supplier we can in the products we make and the services we provide. For more information on Martinrea, please visit www.martinrea.com.

MEDIA CONTACT:
Deanna Lorincz
Global Director, Communications and Marketing
deanna.lorincz@martinrea.com
Mobile: 586.634.1766

INVESTOR RELATIONS:
Neil Forster
Director, Investor Relations and Corporate Development
neil.forster@martinrea.com
Tel: 647.210.2385

BOCA RATON, FL, Nov. 11, 2026 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company”), the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced the promotion of John Han to Chief Operating Officer (COO), in addition to his existing role as Chief Financial Officer (CFO).

Since joining DeFi Dev Corp., John has played a central role in the Company’s financial and operational development, helping guide its growth as a publicly traded Solana treasury company. His leadership has been instrumental in overseeing the Company’s financial strategy, capital markets activities, corporate finance, and financial reporting, while contributing to the execution of key strategic initiatives across the organization.

“John has been an integral part of building and scaling DeFi Dev Corp., and his contributions extend well beyond the traditional responsibilities of a CFO,” said Joseph Onorati, Chief Executive Officer of DeFi Development Corp. “His extensive financial background, demonstrated financial acumen, and disciplined approach to execution make him exceptionally well-suited to help lead our next phase of growth, particularly as we advance our bold new capital markets strategy centered around CHAD. Expanding John’s role to Chief Operating Officer is a natural evolution of the leadership he has already demonstrated.”

In his expanded role as Chief Operating Officer and Chief Financial Officer, John will oversee the Company’s day-to-day business operations, organizational execution, and cross-functional coordination, while continuing to lead its financial strategy, capital markets activities, and financial reporting. His expanded responsibilities will help strengthen the Company’s operational infrastructure, improve execution across strategic initiatives, and support DeFi Dev Corp.’s continued growth as it advances its Solana treasury strategy and broader business objectives.

About DeFi Development Corp.
DeFi Development Corp. (Nasdaq: DFDV) has adopted a treasury policy under which the principal holding in its treasury reserve is allocated to SOL. Through this strategy, the Company provides investors with direct economic exposure to SOL, while also actively participating in the growth of the Solana ecosystem. In addition to holding and staking SOL, DeFi Development Corp. operates its own validator infrastructure, generating staking rewards and fees from delegated stake. The Company is also engaged across decentralized finance (DeFi) opportunities and continues to explore innovative ways to support and benefit from Solana’s expanding application layer.

The Company is also an AI-powered online platform that connects the commercial real estate industry by providing value-add services and software subscriptions to multifamily and commercial property professionals, as the Company connects the increasingly complex ecosystem that stakeholders have to manage. The Company’s data and software offerings are generally offered on a subscription basis as software as a service.

Investor Contact:
ir@defidevcorp.com

Media Contact:
press@defidevcorp.com

WILMINGTON, Del., Nov. 11, 2026 (GLOBE NEWSWIRE) — Onfolio Holdings Inc. (Nasdaq: ONFO, ONFOW) (OTC: ONFOP) (the “Company” or “Onfolio”), an owner-operator of cash-generative online businesses, will hold a conference call on Tuesday, November 17, 2026, at 8:00 a.m. Eastern time to discuss its financial results for the third quarter ended September 30, 2026.

Onfolio’s financial results will be reported in a press release prior to the conference call. The Company’s management will host the conference call, followed by a live question and answer period. A replay of the conference call will be available via the webcast link below following the live call.

Date: Tuesday, November 17, 2026
Time: 8:00 a.m. Eastern time
Webcast Link: Here
Dial-In Link: Here
Toll-free dial-in number: 1-877-704-4453
International dial-in number: 1-201-389-0920
Conference ID: 13763317

Please call one of the conference telephone numbers 5–10 minutes prior to the start time, and an operator will register your name and organization. Alternatively, you can connect instantly to the event via the webcast link or dial-in link above.

About Onfolio Holdings
Onfolio Holdings Inc. acquires and operates online businesses in sectors including marketing, education and e-commerce. Its approach emphasizes sustainable cash generation and building long-term value. Onfolio also applies artificial intelligence to improve its businesses, create internal tools and develop products. Additional information is available at www.onfolio.com.

Investor Contact
investors@onfolio.com